Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07009262 · ClinicalTrials.gov registry record
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
A clinical trial, sponsored by KalVista Pharmaceuticals.
- Completed
- Registry status
- 88
- Enrollment target
NCT07009262 is a clinical trial that has completed, run by KalVista Pharmaceuticals. The registered enrollment target is 88 participants.
The verdict
NCT07009262 has completed, sponsored by KalVista Pharmaceuticals.
- COMPLETED
- Registry status
- 88 participants
- Enrollment target
Study Summary
Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.
Interventions
- OTHER Inapplicable
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2025-11-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07009262
The ClinicalTrials.gov registry entry for NCT07009262 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is KalVista Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inapplicable is the first listed.
NCT07009262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07009262 about?
NCT07009262 is a clinical study titled "A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks". Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and sever...
What is the current status of trial NCT07009262?
This trial is currently completed. The enrollment target is 88 participants. The study started on 2025-04-21. Estimated completion is 2025-11-25.
What interventions are being tested in trial NCT07009262?
The interventions under investigation include: Inapplicable (OTHER).
Who is sponsoring clinical trial NCT07009262?
This trial is sponsored by KalVista Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.